Developer docs
API playgroundTry for free, no card

Search company profiles

Casdin Capital

Full company profile

uuid00006hf

Namestring
Casdin Capital
Legal namestring
Casdin Capital, LLC
Websiteurl
casdincapital.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that conducts fundamental research and invests across the life sciences value chain, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology subsectors such as life science tools, diagnostics, drug developers, molecular medicine, and data platforms. The firm serves institutional investors, family offices, and high-net-worth individuals seeking specialized exposure to innovative life sciences companies, generating revenue through traditional investment management fees and performance allocations (private placement model) without publicly disclosed pricing.

The firm's core offering is its investment research platform and portfolio construction capabilities rather than a software product. It operates with a deliberately lean 11–50 person team structured around a full C-suite (CIO/Founder Eli Casdin; CFO Lawrence Canzoneri; COO Alexandria Fisk; CMO Kelly Axsom, MD; CCO Angelo Crupi; GC Steve Giordano) plus dedicated research (Suzanne Angell, Shaun Rodriguez PhD), trading (Brad Weisgerber), business development and investor relations (Randy White), and technology (Scott Bryan) functions. Casdin distributes exclusively through direct outreach to qualified purchasers and supports existing LPs via a password-protected member portal carrying quarterly partner letters, coffee talk interviews, and presentation archives.

Recent portfolio activity demonstrates active capital deployment across both private rounds and public-market positions, including disclosed stakes in Relay Therapeutics (~$110 million as of February 2026), GeneDx (200,000 shares worth approximately $11.1 million in June 2026), and 2025–2026 Series B participation in City Therapeutics ($99.5 million, co-led), Beacon Biosignals (oversubscribed at $86 million, then expanded past $97 million), Apella ($80 million), and Adlai Nortye ($140 million PIPE). Casdin frequently co-invests alongside elite healthcare and technology investors including ARCH Venture Partners, Fidelity Management, Viking Global Investors, Sofinnova, Cormorant Asset Management, Google Ventures, General Catalyst, Takeda, and Catalio Capital Management, and is advised by a scientific advisory board including Nobel laureate William G. Kaelin, Jr., MD and other translational medicine experts.

Short descriptiontext

Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that invests across healthcare, biotechnology, synthetic biology, and technology for institutional investors, family offices, and high-net-worth individuals seeking life sciences exposure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences investing, healthcare investment management, biotechnology venture capital, fundamental equity research, hedge fund management
Industry2 codes
1Sector/Thematic Equity (Active)
CodeFSAAAIAGPrimaryYes
2Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryNo
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Investment Management
Social media profiles2 records
Revenue model1 record
1Investment Management
TypeSubscription Recurring
Description

Casdin Capital generates revenue through investment management fees and performance allocations from its life sciences-focused investment strategies, serving institutional investors and high net worth individuals seeking exposure to the healthcare, biotechnology, synthetic biology, and technology sectors.

casdincapital.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Casdin Capital is a fundamental research-driven investment management firm that builds and manages portfolios concentrated in the life sciences sector, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology. The firm deploys capital across public equities and private venture financings in companies advancing molecular medicine, genomics, diagnostics, and life-sciences information platforms, and serves institutional investors, family offices, and high net worth individuals seeking specialized exposure to the life-sciences investment theme.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Casdin Capital is a life sciences investment firm that provides investment management services. The firm does not operate a traditional software product platform. Its offerings consist of investment funds, venture capital activities, and investor relations services including a password-protected member portal containing quarterly partner letters, coffee talk presentations, and investment conference materials.

Product and service4 records
1Life Sciences Fundamental Research Investment Strategy
CategoryInvestment Management
Description

Fundamental research-driven investment management strategy concentrated on life sciences, covering Healthcare, Biotechnology, Synthetic Biology, and Technology subsectors, and offered to institutional investors, family offices, and high net worth individuals.

2Life Sciences Venture Capital Participations
CategoryVenture Capital
Description

Private venture capital financings into life-sciences companies across molecular medicine, genomics, diagnostics, and life-sciences information platforms, including participation in rounds for City Therapeutics, Beacon Biosignals, Apella, Octave Bioscience, and Adlai Nortye.

3Public Equities Investment in Life Sciences
CategoryPublic Equities
Description

Public equity investments in life-sciences issuers, including significant positions such as the Casdin Capital stake in Relay Therapeutics valued at approximately $110 million and the acquisition of 200,000 shares of GeneDx Holdings Corp valued at approximately $11.1 million.

4Member Portal Investor Communications
CategoryInvestor Relations
Description

Password-protected member portal providing existing investors with quarterly partner letters, coffee talk interviews with industry leaders, and presentation archives from Casdin Capital Spotlight events.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles28 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment259 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Casdin Capital

Life Sciences Investment Managementcasdincapital.com

Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that invests across healthcare, biotechnology, synthetic biology, and technology for institutional investors, family offices, and high-net-worth individuals seeking life sciences exposure.

What Casdin Capital does

Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that conducts fundamental research and invests across the life sciences value chain, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology subsectors such as life science tools, diagnostics, drug developers, molecular medicine, and data platforms. The firm serves institutional investors, family offices, and high-net-worth individuals seeking specialized exposure to innovative life sciences companies, generating revenue through traditional investment management fees and performance allocations (private placement model) without publicly disclosed pricing.

The firm's core offering is its investment research platform and portfolio construction capabilities rather than a software product. It operates with a deliberately lean 11–50 person team structured around a full C-suite (CIO/Founder Eli Casdin; CFO Lawrence Canzoneri; COO Alexandria Fisk; CMO Kelly Axsom, MD; CCO Angelo Crupi; GC Steve Giordano) plus dedicated research (Suzanne Angell, Shaun Rodriguez PhD), trading (Brad Weisgerber), business development and investor relations (Randy White), and technology (Scott Bryan) functions. Casdin distributes exclusively through direct outreach to qualified purchasers and supports existing LPs via a password-protected member portal carrying quarterly partner letters, coffee talk interviews, and presentation archives.

Recent portfolio activity demonstrates active capital deployment across both private rounds and public-market positions, including disclosed stakes in Relay Therapeutics (~$110 million as of February 2026), GeneDx (200,000 shares worth approximately $11.1 million in June 2026), and 2025–2026 Series B participation in City Therapeutics ($99.5 million, co-led), Beacon Biosignals (oversubscribed at $86 million, then expanded past $97 million), Apella ($80 million), and Adlai Nortye ($140 million PIPE). Casdin frequently co-invests alongside elite healthcare and technology investors including ARCH Venture Partners, Fidelity Management, Viking Global Investors, Sofinnova, Cormorant Asset Management, Google Ventures, General Catalyst, Takeda, and Catalio Capital Management, and is advised by a scientific advisory board including Nobel laureate William G. Kaelin, Jr., MD and other translational medicine experts.

Casdin Capital firmographics

Firmographics
Name
Casdin Capital
Legal name
Casdin Capital, LLC
Website
https://casdincapital.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Casdin Capital is a private, New York-based investment management firm founded in 2012 by Eli Casdin that invests across healthcare, biotechnology, synthetic biology, and technology for institutional investors, family offices, and high-net-worth individuals seeking life sciences exposure.
Ownership category
akta.pro rank

Casdin Capital industry classification

Industry
Product category
Life Sciences Investment Management
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro primary industry
Sector/Thematic Equity (Active) (FSAAAIAG)
akta.pro secondary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Life sciences investing
  • Healthcare investment management
  • Biotechnology venture capital
  • Fundamental equity research
  • Hedge fund management

Where Casdin Capital is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Casdin Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Investment Management: Casdin Capital generates revenue through investment management fees and performance allocations from its life sciences-focused investment strategies, serving institutional investors and high net worth individuals seeking exposure to the healthcare, biotechnology, synthetic biology, and technology sectors.

Distribution channels1 record

Marketing channels3 records

Casdin Capital product offering

Product offering

Core offering

Casdin Capital is a fundamental research-driven investment management firm that builds and manages portfolios concentrated in the life sciences sector, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology. The firm deploys capital across public equities and private venture financings in companies advancing molecular medicine, genomics, diagnostics, and life-sciences information platforms, and serves institutional investors, family offices, and high net worth individuals seeking specialized exposure to the life-sciences investment theme.

Product overview

Casdin Capital is a life sciences investment firm that provides investment management services. The firm does not operate a traditional software product platform. Its offerings consist of investment funds, venture capital activities, and investor relations services including a password-protected member portal containing quarterly partner letters, coffee talk presentations, and investment conference materials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Life Sciences Fundamental Research Investment Strategy Fundamental research-driven investment management strategy concentrated on life sciences, covering Healthcare, Biotechnology, Synthetic Biology, and Technology subsectors, and offered to institutional investors, family offices, and high net worth individuals.
  • Life Sciences Venture Capital Participations Private venture capital financings into life-sciences companies across molecular medicine, genomics, diagnostics, and life-sciences information platforms, including participation in rounds for City Therapeutics, Beacon Biosignals, Apella, Octave Bioscience, and Adlai Nortye.
  • Public Equities Investment in Life Sciences Public equity investments in life-sciences issuers, including significant positions such as the Casdin Capital stake in Relay Therapeutics valued at approximately $110 million and the acquisition of 200,000 shares of GeneDx Holdings Corp valued at approximately $11.1 million.
  • Member Portal Investor Communications Password-protected member portal providing existing investors with quarterly partner letters, coffee talk interviews with industry leaders, and presentation archives from Casdin Capital Spotlight events.

Companies that use Casdin Capital

Customer profile

Segments1 record

Ideal customer profiles2 records

Casdin Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Casdin Capital partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Casdin Capital competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Casdin Capital social profiles

Digital presence

Casdin Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Casdin Capital leadership team

Management profile

Number of profiles

Profiles28 records

Casdin Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Casdin Capital M&A and investment

M&A and investment

M&A

Investments259 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Casdin Capital

What does Casdin Capital do?

Casdin Capital is a fundamental research-driven investment management firm that builds and manages portfolios concentrated in the life sciences sector, spanning Healthcare, Biotechnology, Synthetic Biology, and Technology. The firm deploys capital across public equities and private venture financings in companies advancing molecular medicine, genomics, diagnostics, and life-sciences information platforms, and serves institutional investors, family offices, and high net worth individuals seeking specialized exposure to the life-sciences investment theme.

Is Casdin Capital a public or private company?

Casdin Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Casdin Capital founded?

Casdin Capital was founded in 2012. It employs 11 to 50 people.

Where is Casdin Capital based?

Casdin Capital is headquartered in New York, United States, in the North America region.

How does Casdin Capital make money?

One revenue line is on record: investment Management.

Does Casdin Capital have an API?

No public API is recorded for Casdin Capital.

What industry is Casdin Capital in?

Casdin Capital's product category is Life Sciences Investment Management. Its primary akta.pro industry code is FSAAAIAG, Sector/Thematic Equity (Active), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineFlare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive OfficerFlare Therapeutics closed an $85 million Series C financing led by Third Rock Ventures and Nextech Invest, appointing Anna Protopapas as CEO. Proceeds will advance FX-111, an ARON degrader for prostate cancer, with FDA IND clearance and expected Phase 1A in Q3 2026.GlobeNewswireBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementBoundless Bio and Serapha Bio announced an all-stock merger, with Serapha to operate as the combined company. Serapha secured $230 million in pre-closing private investments, and the deal is expected to close in Q4 2026. The combined company will focus on SERP-01, a base editing therapy for Alpha-1 Antitrypsin Deficiency.FierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series BCity Therapeutics, a Massachusetts biotech founded in 2024 by former Alnylam Pharmaceuticals RNAi pioneers, has raised $99.5 million in Series B funding led by new investors Viking Global Investors, Sofinnova Investments, Casdin Capital and NYBC Ventures, alongside existing backers Regeneron Ventures, Arch Venture Partners and Fidelity Management & Research. The financing will fund clinical development of the company's lead Phase 1 candidate targeting Factor XI (a blood-clotting protein) with first data readout expected in Q4 2025, and is intended to fund operations through 2027. City aims to differentiate itself in the crowded RNAi space by developing extra-hepatic delivery technology to target tissues beyond the liver, with plans to supplement the raise through additional partnerships similar to existing deals with Bausch + Lomb and Biogen.Venture Capital Access OnlineCity Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi TherapeuticsCity Therapeutics completed a $99.5 million Series B financing led by Viking Global Investors and Sofinnova Investments. Proceeds will advance its RNAi pipeline, including a Phase 1 trial of CITY-FXI and two programs entering the clinic by 2026. The company has raised over $230 million from investors.Business Wire BlogCity Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi TherapeuticsCity Therapeutics closed a $99.5 million Series B financing led by Viking Global Investors and Sofinnova Investments, with existing investors participating. Proceeds will advance its RNAi pipeline, including a Phase 1 trial of CITY-FXI and two programs entering the clinic by year-end 2026.Investing.comTop insider buys and sells disclosed for Thursday By Investing.comUS public market insider trading activity disclosed on May 21, 2026 revealed significant transactions across multiple companies, including Gold.com insiders acquiring $5.7 million in shares and Astera Labs President Sanjay Gajendra selling approximately $69.77 million in stock near the company's 52-week high. Notable sales also included Cloudflare CEO Matthew Prince selling $32.6 million in shares and CoreWeave CEO Michael Intrator selling $30.2 million, while investment firms Voss Capital, Crestview Partners, and Casdin Capital executed additional transactions totaling nearly $1 million to $61.5 million respectively. The roundup covers insider buying by directors and shareholders alongside routine Rule 10b5-1 plan executions across ten companies.Investing.comCasdin Capital, Eli Casdin sell $28.1m in NASDAQ:BLFS stock By Investing.comCasdin Capital, LLC and its affiliated entities sold 1.2 million shares of BioLife Solutions Inc (NASDAQ:BLFS) over three days from May 19–21, 2026, generating approximately $28.1 million at prices ranging from $22.65 to $23.70 per share. The reporting entities collectively hold 4,757,165 shares following the transactions, with the stock currently trading at $24.75, representing a 17.5% gain over the past week. Separately, BioLife Solutions reported Q1 2026 revenue of $27.5 million, exceeding analyst forecasts by 7.09%, while EPS remained stable at $0.02.Investing.comCasdin Capital, Eli Casdin sell $28.1m in NASDAQ:BLFS stock By Investing.comCasdin Capital, LLC and its affiliated entities Casdin Partners Master Fund, L.P. and Casdin Partners GP, LLC sold a combined 1.2 million shares of BioLife Solutions Inc (NASDAQ:BLFS) for approximately $28.1 million over three trading days from May 19 to May 21, 2026, at prices between $22.65 and $23.70 per share. Following the transactions, the reporting entities collectively hold 4,757,165 shares of BioLife Solutions, which has a market capitalization of $1.2 billion and a beta of 1.97. The stock currently trades at $24.75, reflecting a 17.5% gain over the past week, as the company also reported Q1 2026 revenue of $27.5 million, beating analyst forecasts by 7.09%.Pulse 2.0Apella: $80 Million Raised To Bring Ambient AI And Computer Vision Into the Operating RoomApella, a health technology company focused on operating room operations, raised $80 million in Series B financing led by HighlandX, with participation from Vensana Capital, Casdin Capital, K2 HealthVentures, OpAmp Capital, and customer Houston Methodist. The company's ambient AI platform uses computer vision to automatically capture surgical workflow data and write it back to electronic health records, helping hospitals improve operational efficiency; customers report an average 5% increase in surgical volume. Apella is scaling beyond initial pilots to enterprise deployments across multiple health systems and procedural areas including interventional radiology, cardiology, and endoscopy.FinSMEsApella Raises $80M in Series B Equity and Venture DebtApella, a San Francisco-based health technology company, raised $80 million in Series B equity and venture debt, led by HighlandX with participation from returning investors Vensana Capital, Casdin Capital, PFM Health Sciences, Upside Partnership, Operator Partners, and new investors K2 HealthVentures and OpAmp Capital. The company intends to use the funds to expand operations and development of its ambient video intelligence platform that provides hospitals with real-time operational intelligence. Apella's technology, which integrates ambient AI with EHR data to support surgical teams, recently expanded with Horizon offering case duration predictions and utilization data.